Kevin McCoy

USA TODAY

NEW YORK — Pharma industry entrepreneur Martin Shkreli pleaded not guilty Monday to an updated indictment that added a new conspiracy charge to the criminal allegations against him — then jeered at federal prosecutors in a live-streamed exchange.

The allegation added new details to the December indictment that alleged Shkreli, 33, illegally took stock from Retrophin, the New York-based biotechnology firm he launched in 2011 and was ousted from three years later. He's accused of using the funds to pay unrelated debts in other business ventures.

Filed in Brooklyn federal court, the superseding indictment alleges that Shkreli and co-defendant Evan Greebel, a former outside counsel at Retrophin, conspired to defraud potential investors in the San Diego-based company by hiding Shkreli's secret ownership of company stock that appeared to be allocated to seven employees.

Greebel, 42, also pleaded not guilty as U.S. District Judge Kiyo Matsumoto arraigned both men on the latest charge.

In December, Shkreli similarly pleaded not guilty to initial securities fraud, wire fraud and conspiracy charges that he siphoned millions of dollars from Retrophin to repay investors who were defrauded in two defunct hedge funds that had focused on health care investments. He entered similar pleas to allegations that he used company funds to settle personal disputes with investors, unjustly enriched himself with Retrophin funds and formed false ties to consultants.

Prosecutors and defense lawyers were unable to reach agreement during Monday's hearing on tentative dates for pre-trial motions or for the timing of the trial itself. Matsumoto set a new status conference for July 14.

Shkreli did not comment as he left the courthouse. Despite lead defense attorney Benjamin Brafman's previous instructions not to discuss the case, the habitually unavoidable-for-comment Shkreli unloaded as he spoke to customers at a Manhattan Dunkin' Donuts outlet while live-streaming on Periscope.

"It went great. The judge b----slapped the government, again," Shkreli bragged of the hearing.

Martin Shkreli @MartinShkreli

Earlier, Brafman said: "I do not believe that the new count in the indictment with respect to Mr. Shkreli adds anything of value to the flawed theory of the case against Mr. Shkreli personally." The attorney did not immediately respond to a message seeking comment about Shkreli's social media remark.

Shkreli, CEO slammed over drug prices, $5M bond

The criminal charges are unrelated to the episode that brought Shkreli national prominence: Using his role as CEO of Turing Pharmaceuticals to orchestrate a 5,000% price hike of a medication called Daraprim. The prescription drug is used to treat toxoplasmosis, a parasitic disease that affects AIDS patients, pregnant women and others who have weakened immune systems.

The Shekreli-led decision to raise the per-pill cost of Daraprim from $13.50 to $750 has sparked widespread criticism from patients, medical professionals and even some 2016 U.S. presidential candidates.